Design, Development of Probiotic Gummies and Determining the Stability of Gummies

Main Article Content

Abstract

Probiotics have been said to assist healthy immunological and digestive systems. B.coagulans has become a focus of research due to its high temperature stable, highly viable, economical and Versatile in nature. The ultimate objective of the present research work is to incorporate B.coagulans strain into the gummies, which will benefit the human health. Gummies are formulated by Trio method. Optimization studies for ingredients was carried out to determine the concentration which is ideal for the preparation. Two different formulations were prepared with the help of Optimization data using sucrose, gelatin and pectin as the base for the preparation of gummies. All the prepared probiotic gummies were subjected to various evaluation parameters like pre-formulation studies, microbial analysis, nutritional facts and Stability data. The results of microbial analysis shows that viability of probiotic in gummy is not less than 500 million spores /gummy, total yeast and mold count is < 10 Cfu /gummy and Pathogen are absent in the formulations. Nutritional facts determines the content like Carbohydrate and Total Sugar content varied from 75.1% to 82.76% w/w and 65.4% to 79.91% w/w. Fat and protein in gummies with B.coagulans varied from 0.03 % to 0.78 % and 9.9 % to < 1%, respectively. The energy value of gummies varied from 338 kcal/100 g to 340 kcal/100gm. Short-term stability Studies indicate that there are no significant changes in physical characteristics, viable count, traces of yeast & mold and pathogens after 180 days of storage at 25±2⁰ C with 60±5% RH. 

References

FAO/WHO.

Evaluation of health and nutritional properties of B. coagulans and live lactic acid bacteria; Food and Agriculture Organization of the United Nations and World Health Organization Expert Consultation Report: 2001.

Maathuis A, Keller D, Farmer S.

Survival and metabolic activity of the GanedenBC30 strain of Bacillus coagulans in a dynamic in vitro model of the stomach and small intestine.

Beneficial Microbes. 2010;1(1):31–36.

Cao J, Yu Z, Liu W, Zhao J, Zhang H, Zhai Q, Chen W.

Probiotic characteristics of Bacillus coagulans and associated implications for human health and diseases.

Journal of Functional Foods. 2020;64:103643.

Nicholson WL, Munakata N, Horneck G, Melosh HJ, Setlow P.

Resistance of Bacillus endospores to extreme terrestrial and extraterrestrial environments.

Microbiology and Molecular Biology Reviews. 2000;64(3):548–572.

Fenster K, Freeburg B, Hollard C, Wong C, Rønhave Laursen R, Ouwehand AC.

The production and delivery of probiotics: A review of a practical approach.

Microorganisms. 2019;7(3):83.

Bora PS.

Physicochemical Properties and Excipient Compatibility Studies of Probiotic Bacillus coagulans Spores.

Scientia Pharmaceutica. 2009;77(3):625–637.

Adibpour N, Hosseininezhad M, Pahlevanlo A, Hussain MA.

A review on Bacillus coagulans as a spore-forming probiotic.

Applied Food Biotechnology. 2019;6(2):91–100.

Konuray G, Erginkaya Z.

Potential use of Bacillus coagulans in the food industry.

Foods. 2018;7(6):92.

Bressuire-Isoard C, Broussolle V, Carlin F.

Probiotic gummies benefits and best types.

Microbiology Reviews. 2018;42(5):614–626.

Ohye DF, Murrell WG.

Formation and structure of the spore of Bacillus coagulans.

The Journal of Cell Biology. 1962;14(1):111–123.

Mazkour S, Shekarforoush SS, Basiri S.

The effects of supplementation of Bacillus subtilis and Bacillus coagulans spores on intestinal microflora and growth performance in rat.

Iranian Journal of Microbiology. 2019;11(3):260.

Maathuis AJH, Keller D, Farmer S.

Survival and metabolic activity of the GanedenBC30 strain of Bacillus coagulans in a dynamic in vitro model of the stomach and small intestine.

Beneficial Microbes. 2010;1:31–36.

AOAC International.

Official Methods of Analysis of AOAC International. 17th edition, 2nd revision.

Gaithersburg, MD, USA: Association of Analytical Communities; 2003.

International Conference on Harmonisation (ICH).

Stability testing of new drug substances and products; harmonised tripartite guideline.

2003. (Pharmaguideline.net)